Skip to main content

Table 2 Susceptibility loci associated with type 2 diabetes mellitus complications

From: Novel susceptibility loci identified in a genome-wide association study of type 2 diabetes complications in population of Latvia

CHR

Closest gene

SNP

A1/A2

OR (95% CI)

P-value

MAF cases/controls

MAF European

Diabetic neuropathy

4:145030546

GYPA

rs1132787

T/C

2.71 (2.02–3.64)

3.23E−11

0.37/0.16

0.31

17:15733545

LOC105371557

rs522521

A/C

0.49 (0.38–0.64)

5.07E−08

0.37/0.56

0.70

Macrovascular complications

1:144936353

PDE4DIP

rs2477088

T/C

2.50 (1.87–3.34)

6.11E−10

0.51/0.32

0.58

17:15733545

LOC105371557

rs522521

A/C

0.42 (17.32–0.56)

6.95E−10

0.40/0.60

0.70

2:73870010

NAT8

rs4852954

T/C

2.27 (2.71–3.01)

1.26E−08

0.50/0.31

0.61

1:169511555

F5

rs6032

T/C

2.12 (1.63–2.77)

2.62E−08

0.56/0.37

0.73

6:167114208

RPS6KA2

rs6935464

A/G

2.25 (6.69–3.01)

3.89E−08

0.44/0.26

0.57

18:14150724

ZNF519

rs7236163

T/C

2.14 (18.63–2.82)

4.97E−08

0.46/0.27

0.58

7:76764970

CCDC146

rs3095447

A/C

2.16 (7.64–2.84)

4.98E−08

0.55/0.37

0.79

Ophthalmic complications

7:76764970

CCDC146

rs3095447

A/C

2.18 (1.66–2.87)

2.55E−08

0.61/0.40

0.79

  1. CHR chromosome and base pair position in Human Genome build hg19, A1 minor allele, A2 major allele, OR odds ratio for the minor allele, CI confidence interval 95%, MAF minor allele frequency, MAF European minor allele frequency observed in the European population [31]
Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us